Once‐weekly semaglutide use in patients with type 2 diabetes: Real‐world data from the SURE Italy observational study
Authors' conclusion
In routine clinical practice in Italy, patients with T2D treated with once-weekly semaglutide for 30 weeks achieved clinically significant improvements in HbA1c, body weight and other outcomes.
Study context
- Population
- Adults with T2D and ≥1 documented HbA1c within 12 weeks of semaglutide initiation, routine clinical practice in Italy491 completed on treatment (effectiveness analysis set (EAS))
- Participants
- 579 adults
- Outcome
- Change in HbA1c from baseline to end of study (EOS)
- Follow-up
- ≈30 weeks
Methodological detailsmulticentre, open-label
- Multicentre
- Open-label
Main finding
As reported in the abstract
Change in HbA1c · EOS
Mean HbA1c decrease
1.1%-point
95% CI 1.20, 1.05P < .0001
Observational data: associations, not effects.
Further findings
Change in body weight · end of study (EOS)
- Mean body weight decrease
- 4.2 kg (95% CI 4.63, 3.67; P < .0001)
- EAS
Proportions achieving targets · EOS
- HbA1c <7.0%
- 61.7%
- HbA1c <6.5%
- 40.8%
- Weight loss ≥5%
- 40.5%
- Post-hoc composite (HbA1c reduction ≥1%-point and weight loss ≥5%)
- 25.3%
Patient-reported outcomes · baseline to EOS
- Patient-reported outcomes improved
Original publication
Once‐weekly semaglutide use in patients with type 2 diabetes: Real‐world data from the SURE Italy observational study. Diabetes Obes Metab. Published 12 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →